Soligenix, Inc. (SNGX)

Soligenix's stock price has experienced significant volatility and a substantial decline over the past six months. Key events impacting the stock include the halting of the Phase 3 FLASH2 trial for HyBryte™ due to futility, which led to a significant drop in stock price. Positive clinical results from a comparative study evaluating HyBryte™ against Valchlor® in CTCL were published, having a minor negative impact on the stock. Soligenix announced recent accomplishments and year-end 2025 financial results, which saw an increase in stock price. The company received Orphan Drug Designation from the European Commission for SGX945 for the treatment of Behçet's Disease. Soligenix announced recent updates and first-quarter 2026 financial results, reporting a net loss of $2.8 million with no revenue, and stated substantial doubt about its ability to continue as a going concern without additional financing. Soligenix experienced substantial shareholder dilution, with total shares outstanding increasing significantly.

There is no indication of demand seasonality for Soligenix, Inc.'s products and services. Demand for its products would likely be driven by medical need and public health initiatives rather than seasonal patterns.

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs, operating within the pharmaceutical preparation manufacturing industry. Its business is structured around two primary segments: Specialized BioTherapeutics, which focuses on treatments for orphan diseases like HyBryte™ for CTCL and SGX945 for oral mucositis, and Public Health Solutions, dedicated to vaccine and biodefense programs such as RiVax® and CiVax™.

Soligenix, Inc. is incorporated in Delaware and headquartered in Princeton, New Jersey, United States. The company focuses on both the U.S. and European markets for its specialized biotherapeutics, and its Public Health Solutions segment focuses on national and international public health initiatives.

Soligenix's brand reputation has likely been significantly impacted by the clinical setback of HyBryte™, with the halting of the Phase 3 FLASH2 trial for futility creating a "catastrophic clinical setback" and "going concern risk." This event has undermined the company's near-term commercial prospects and cast a negative light on its reputation.

The ownership structure of Soligenix (SNGX) stock includes institutional, retail, and individual investors. Institutional owners hold a small percentage of the company's stock, with major shareholders including DRW Securities, LLC, and Vanguard Group Inc. The general public, primarily retail investors, holds a substantial stake. Insiders own a small percentage of the company's stock, with Robert J. Rubin owning the most shares among insiders.